Skip to main content

Kaer NewsHealth

Two new Ebola vaccines to join DR Congo trial as deaths pass 5,100

WHO recommends adding Oxford and Moderna vaccines to the Tumaini trial in DR Congo, where 5,126 have died from Bundibugyo Ebola.

4 min read
Two new Ebola vaccines to join DR Congo trial as deaths pass 5,100Photo: Premium Times

Key points

Two new Ebola vaccines will join the Tumaini trial in DR Congo, where 5,126 have died from Bundibugyo Ebola.

The World Health Organisation has recommended adding two new Ebola vaccine candidates to the Tumaini clinical trial in the Democratic Republic of Congo, where 5,126 people have died from the Bundibugyo strain. The vaccines, ChAdOx1 and mRNA-1469, will be evaluated during an active Bundibugyo outbreak for the first time. The recommendation came from the WHO's independent Technical Advisory Group on Candidate Vaccines Prioritisation.

The outbreak, which has continued for almost six months, is the largest in the country's history. As of 1 November, more than 10,500 confirmed infections and 5,126 deaths had been recorded. The two new candidates will join the trial once national regulatory approvals have been secured, which is expected to happen quickly as the DRC contends with the escalating crisis.

Vaccines and trial design

ChAdOx1 was developed by the University of Oxford in partnership with the Serum Institute of India. mRNA-1469 was developed by Moderna. The Tumaini trial, which means 'hope' in Swahili, is already testing MSD's Ervebo vaccine, approved to protect against the Zaire Ebola species, to see if it also works against Bundibugyo. Expanding the trial means vaccines specifically designed for Bundibugyo will be evaluated during an active outbreak for the first time.

The Tumaini trial began in Bunia, the capital of Ituri province, on 23 October. It is designed to evaluate multiple vaccine candidates within a single trial using a ring-vaccination approach. This strategy enrols contacts of people with confirmed Bundibugyo virus disease, along with other individuals linked to those contacts. Four vaccination rings have been established in the DRC, with several more being prepared.

WHO Director-General Dr Tedros Adhanom Ghebreyesus said: "The fact that these vaccines are ready to enter clinical trials is a testament to the power of science and partnership." He added: "Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control." The WHO and partners used the same ring-vaccination approach during the West African Ebola outbreak a decade ago.

Evidence from early trials

Moderna's mRNA-1469 has been put forward on the back of a phase 1 trial in Canada, carried out in healthy adults aged 18 to 65, which showed it was able to stimulate Bundibugyo-specific binding antibody responses. ChAdOx1 has gone through initial testing in adults aged 18 to 55 at sites in the UK and Uganda, and has also stimulated encouraging antibody responses. These early results support the decision to advance both candidates.

The Ervebo vaccine, developed to protect against the Zaire Ebola species, is already being assessed to determine whether it offers protection against Bundibugyo Ebola. A trial in Guinea during the West African outbreak established the effectiveness of Ervebo against Zaire Ebola. The new candidates will add to the evidence base for controlling the current outbreak.

Research into possible treatments is also progressing. Another study, called PARTNERS, is testing potential drug therapies for people diagnosed with the virus, alone or in combination, to see if they can improve survival rates. Initial findings from the treatment trial are expected in the coming months, with results from the vaccine trial due in early 2027.

Treatment research and next steps

The WHO said the new candidates could provide an important tool in controlling the outbreak, although they will require national approval before joining the ongoing trial. The outbreak, caused by the rare Bundibugyu species, has no approved vaccine or specific treatment, complicating efforts to contain its spread. The Africa Centres for Disease Control and Prevention has described it as the fastest-growing Ebola outbreak in history.

The addition of the two new vaccines marks a significant step in the response to the outbreak. The Tumaini trial is designed to evaluate several candidates within one trial, using a ring-vaccination approach that focuses on people who have had contact with confirmed Ebola patients. The WHO is supporting the trial as part of broader efforts to contain transmission and reduce deaths.

The next milestone is the completion of national regulatory approvals, which will allow the new vaccines to join the trial. Results from the vaccine trial are due in early 2027, while initial findings from the treatment trial are expected in the coming months. The WHO and partners continue to work with health authorities and humanitarian partners to contain the outbreak.

Frequently asked questions

What is the Tumaini trial?

Tumaini is a phase 2/3 clinical trial in the DRC that evaluates multiple Ebola vaccine candidates using ring vaccination. It began in Bunia on 23 October and is testing vaccines against the Bundibugyo strain.

How many deaths has the DRC Ebola outbreak caused?

As of 1 November, the outbreak has recorded more than 10,500 confirmed infections and 5,126 deaths. It is the largest outbreak in the country's history, caused by the Bundibugyo species.

When will results from the vaccine trial be available?

Results from the vaccine trial are due in early 2027. Initial findings from the PARTNERS treatment trial are expected in the coming months.

More from this edition